ViewRay

ViewRay Shares Outstanding

The The number of shares of ViewRay (VRAYQ) as of Oct 27, 2026 is 183.40 M. In the previous year, The number of shares was 183.40 M — a change of 0.00% (lower).

Shares Outstanding

183.40 M

YoY

0.00%

Last updated:

In 2022, ViewRay had 183.40 M outstanding stocks, a 0.00% change from the 183.40 M stocks in the previous year.

The ViewRay Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2019
183.40 M USD
Jan 1, 2020
183.40 M USD
Jan 1, 2021
183.40 M USD
Jan 1, 2022
183.40 M USD
Jan 1, 2023 (e)
181.36 USD
Jan 1, 2024 (e)
181.36 USD
Jan 1, 2025 (e)
181.36 USD
Jan 1, 2026 (e)
181.36 USD
The ViewRay Shares Outstanding history
YEARShares OutstandingYoY
est181.360.00%
est181.360.00%
est181.360.00%
est181.36-100.00%
183.40 M0.00%
183.40 M0.00%
183.40 M0.00%
183.40 M0.00%
183.40 M0.00%
183.40 M0.00%
183.40 M0.00%
183.40 M0.00%
183.40 M+4.42 B%
4.15-97.72%
182.31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ViewRay Number of shares

ViewRay shares outstanding

The number of shares of ViewRay was 181.36 M in 2025. This indicates how many shares ViewRay is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
114.59 M Stocks
Jan 1, 2020
148.53 M Stocks
Jan 1, 2021
171.22 M Stocks
Jan 1, 2022
181.36 M Stocks
Jan 1, 2023 (e)
181.36 M Stocks
Jan 1, 2024 (e)
181.36 M Stocks
Jan 1, 2025 (e)
181.36 M Stocks
Jan 1, 2026 (e)
181.36 M Stocks

ViewRay Stock analysis

What does ViewRay do? ViewRay Inc. is an American medical technology company based in Cleveland, Ohio. It was founded in 2004 by Ivor Jankovic and specializes in the manufacturing of radiation therapy devices. The history of ViewRay begins with the idea of developing innovative technology to treat cancer patients more effectively and gently. In 2005, the company entered into an agreement with the Cleveland Clinic Lerner Research Institute to conduct research on a novel magnetic resonance-guided radiation therapy machine. The research project was led by James F. Dempsey, Chair of the Department of Radiation Oncology at the Cleveland Clinic. In 2009, the first magnetic resonance-guided radiation therapy system was delivered and implemented at the Cleveland Clinic. ViewRay's business model is based on the development and manufacturing of innovative medical devices aimed at making the treatment of cancer patients more effective and gentle. The company focuses on combining magnetic resonance imaging (MRI) and radiation therapy to ensure more precise and safer treatment. ViewRay offers various products, including the MRIdian-Linac system, an advanced radiation therapy device that utilizes MRI technology to provide real-time images of the tumor during radiation. This allows for precise targeting of the tumor while sparing the surrounding tissue. The system also offers the ability to sync radiation therapy with the patient's breathing cycle, further improving the accuracy and effectiveness of the treatment. In addition to the MRIdian-Linac system, ViewRay also offers the MRIdian-MRI system, which is solely dedicated to imaging. The MRIdian-MRI is a diagnostic instrument that allows for better visualization of tissue and tumor studies. The system uses the same MRI technology as the MRIdian-Linac to generate radiation-free images. ViewRay has also specialized in the development of software tools that assist doctors in better planning and monitoring radiation therapy. This includes the RayCare Oncology Information System, which provides a comprehensive workflow and management platform, as well as the RayStation Treatment Planning Software, which enables more precise radiation therapy planning. In terms of market reach, ViewRay has a global presence. The company has a strong presence in North America, Europe, and Asia, and works closely with leading research institutes and hospitals to evaluate and improve the effectiveness and efficiency of its technologies. Overall, ViewRay has developed an innovative and unique portfolio of products and solutions that improve radiation therapy and increase accuracy and safety for patients and doctors. The company is a leader in the development of MRI-guided radiation therapy systems and is expected to continue playing a significant role in the medical technology industry in the future. ViewRay is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating ViewRay's Shares Outstanding

ViewRay's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in ViewRay’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding ViewRay’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in ViewRay’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about ViewRay stock

The number of shares of ViewRay is 183.40 M in 2022.

The number of shares of ViewRay changed from 183.40 M to 183.40 M, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of shares ViewRay since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — ViewRay

All Key Metrics — ViewRay